Related Experiment Video

Updated: May 7, 2026

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

Multicomponent reactions - opportunities for the pharmaceutical industry

Eelco Ruijter, Romano V A Orru

    Drug Discovery Today. Technologies
    |September 21, 2013
    PubMed

    More Related Videos

    Optimization of Radiochemical Reactions using Droplet Arrays10:54

    Optimization of Radiochemical Reactions using Droplet Arrays

    Published on: February 12, 2021

    Diagonal Method to Measure Synergy Among Any Number of Drugs12:08

    Diagonal Method to Measure Synergy Among Any Number of Drugs

    Published on: June 21, 2018

    Related Concept Videos

    Production of Pharmaceuticals01:30

    Production of Pharmaceuticals

    Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
    Drug Metabolism: Phase I Reactions01:17

    Drug Metabolism: Phase I Reactions

    A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
    Phase I Reactions: Oxidation of Carbon-Heteroatom and Miscellaneous Systems01:15

    Phase I Reactions: Oxidation of Carbon-Heteroatom and Miscellaneous Systems

    Oxidative reactions are pivotal in metabolizing numerous compounds, including pharmaceutical drugs. These reactions often occur in carbon-heteroatom systems, such as carbon-nitrogen, carbon-sulfur, and carbon-oxygen.
    In carbon-nitrogen systems, aliphatic and aromatic amines can undergo oxidative reactions. Secondary and tertiary amines, like those found in tricyclic antidepressants, can undergo N-dealkylation, a process that involves the oxidation of the alkyl group. In addition, oxidative...
    Pharmaceutical Poisoning: Potential Scenarios01:26

    Pharmaceutical Poisoning: Potential Scenarios

    Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
    Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

    Biopharmaceutical Factors Influencing Drug Product Design: Overview

    Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
    Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

    Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

    Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...